Daxor (DXR) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 1.99K
• Price to Earnings (P/E): 8.0
• Beta (1Y): 0.60
• Revenue Growth: -97.00%
• EPS Growth: 3.43%
• Country: US
• Employees: 37
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 1.89
• Shares Outstanding: 5,827,225
• 10 Day Avg. Volume: 865
• 30 Day Avg. Volume: 1,994
• PEG Ratio: <0.01
• Price to Book (P/B): 1.60
• Price to Sales (P/S): 146.07
• P/FCF Ratio: -121.66
• Enterprise Value/Market Cap: 10.00T>
• Enterprise Value/Revenue: 390.23
• Enterprise Value/Gross Profit: -679.25
• Enterprise Value/Ebitda: 6.14
• 1Y Price Target: $23.00
• Price Target Upside: 73.19% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -0.04
• Revenue Forecast (FY): $7.00M

• Rating: 55 Neutral
• Price Target: $12.00 ▼(-9.64% Downside)
• Action: Reiterated Date: 03/05/26
• Date: Action: Reiterated 03/05/26

The score is anchored by a very low-debt, well-capitalized balance sheet, but is held back by inconsistent fundamentals—especially weak and volatile cash flows and uneven revenue. Technically, the stock shows bearish momentum (below key moving averages with negative MACD), partly offset by oversold indicators. Valuation looks inexpensive on P/E, while the recent legal compliance filing is a modest positive.

Positive Factors

Balance sheet strength

Extremely low leverage and a sizable equity cushion materially reduce refinancing and solvency risk, giving management durable financial flexibility to fund commercialization, R&D and working capital. This resilience supports multi-month scaling without urgent debt pressures or covenant constraints.

FDA 510(k) clearance for next-gen analyzer

Regulatory clearance for a faster, portable blood volume analyzer is a structural product advantage: it broadens clinical use cases, eases site adoption, and supports reimbursement-driven outpatient deployments. This durable competitive edge can lift sustained revenue as placements scale.

Recent capital raise

A $9M registered direct offering materially strengthens liquidity to build inventory, fund production and expand the commercial team. That capital reduces near-term funding risk and supports execution of commercialization plans over the coming 2–6 months without immediate need for dilutive emergency financings.

Negative Factors

Weak cash generation

Repeated negative operating and free cash flow indicate earnings have not reliably converted to cash, elevating execution risk. Sustained cash burn can force additional funding rounds or slow placements if revenue ramps lag, making near-term scaling contingent on continued external capital.

Volatile, small revenue base

A small, volatile revenue stream and reliance on irregular spikes reduce predictability of margins and cash flow. This unstable top line undermines visibility for commercial scaling and makes multi-quarter performance improvements uncertain until recurring, repeatable revenue is established.

Operating losses from scaling

Ongoing R&D and commercial ramp investments caused operating losses in 2025, showing the commercialization phase is cash-consuming. If product placements or reimbursement uptake lag, continued investment could pressure margins and require further capital before the business achieves sustained operating profitability.

Daxor Business Overview & Revenue Model

Company Description

Daxor Corporation (DXR) is a medical instrumentation and biotechnology company that specializes in blood volume analysis technology. The company focuses on advancing healthcare by providing innovative diagnostic tools and services that enhance the understanding and treatment of various medical conditions. Daxor's flagship product, the BVA-100, is an FDA-cleared diagnostic device that measures human blood volume, aiding in the precise assessment of fluid management in patients.

How the Company Makes Money

Daxor Corporation generates revenue primarily through the sale and leasing of its proprietary blood volume analysis systems, such as the BVA-100. Additionally, the company earns income by providing related services, including testing and analysis of blood samples. This includes contracts with hospitals, clinics, and medical research institutions that utilize their technology for improved clinical decision-making. Daxor may also benefit from partnerships or collaborations with healthcare providers and research organizations that contribute to its growth and market reach. Factors such as regulatory approvals, technological advancements, and the increasing demand for precision in medical diagnostics play a significant role in its revenue generation.

Daxor Financial Statement Overview

Summary

Strong balance sheet with extremely low leverage and a sizable equity cushion supports financial resilience, but earnings quality is pressured by highly volatile revenue and weak/negative operating and free cash flow in multiple years (including 2025), suggesting profits are not consistently converting into cash.

Income Statement

Profitability is headline-strong in the latest annual period (2025) with very high operating and net margins, but the revenue base is small and volatile. Sales declined sharply in 2025 after an exceptionally large 2023 revenue spike, and earlier years include negative revenue and inconsistent margin patterns. Overall, earnings power appears driven by irregular items rather than a stable, repeatable operating trajectory.

Balance Sheet

The balance sheet is a clear strength: leverage is extremely low across periods (debt-to-equity near zero in 2025 and still low historically), and equity represents the vast majority of the capital structure. While profitability on equity has been uneven year-to-year, the company maintains a sizable equity cushion and minimal debt burden, reducing financial risk.

Cash Flow

Cash generation is weak and inconsistent. Operating cash flow is negative in multiple years (including 2025 and 2023), and free cash flow is also negative in those periods, indicating profits are not reliably converting into cash. Although 2024 showed modest positive operating/free cash flow, overall cash flow volatility and recent cash burn elevate execution risk.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	503.42K	2.13M	34.59M	-353.36K	-2.62M
Gross Profit	188.74K	2.13M	34.41M	-1.44M	-3.62M
EBITDA	9.19M	2.06M	329.74K	6.11M	4.75M
Net Income	9.17M	536.33K	280.64K	5.18M	4.75M
Balance Sheet
Total Assets	46.01M	36.63M	34.87M	30.26M	24.98M
Cash, Cash Equivalents and Short-Term Investments	0.00	0.00	0.00	0.00	710.70K
Total Debt	112.00K	729.97K	755.66K	1.23M	3.02M
Total Liabilities	122.59K	840.30K	858.76K	1.29M	3.83M
Stockholders Equity	45.89M	35.79M	34.01M	28.97M	21.15M
Cash Flow
Free Cash Flow	-604.42K	25.69K	-3.66M	-769.30K	-2.76M
Operating Cash Flow	-604.42K	25.69K	-3.66M	-769.30K	-2.76M
Investing Cash Flow	1.18M	1.94M	2.75M	2.69M	74.76K
Financing Cash Flow	-570.94K	-25.69K	3.66M	58.60K	2.85M

Daxor Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 13.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DXR, the sentiment is Negative. The current price of 13.28 is above the 20-day moving average (MA) of 12.19, above the 50-day MA of 12.98, and above the 200-day MA of 11.56, indicating a bearish trend. The MACD of -0.35 indicates Positive momentum. The RSI at 33.83 is Neutral, neither overbought nor oversold. The STOCH value of 10.98 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DXR.

Daxor Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MMSI	68 Neutral	$4.45B	35.21	8.67%	―	11.49%	-2.89%
PDEX	66 Neutral	$152.32M	14.29	30.92%	―	23.65%	120.84%
DXR	55 Neutral	―	8.02	5.26%	―	-97.00%	3.43%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MLSS	42 Neutral	$22.72M	-8.10	-136.47%	―	0.59%	-39.76%
FEMY	41 Neutral	$31.50M	-0.61	-376.23%	―	63.53%	12.49%

Daxor Corporate Events

Daxor Files Legal Opinion Affirming Validity of Stock

Daxor filed a legal opinion from Foley & Lardner LLP regarding the legality of its common stock, indicating that the company has obtained formal legal validation for the issuance or status of its shares. This filing helps reinforce regulatory compliance and may provide additional assurance to investors and other stakeholders about the legitimacy of Daxor’s common stock offering or existing equity structure.

The most recent analyst rating on (DXR) stock is a Hold with a $13.00 price target. To see the full list of analyst forecasts on Daxor stock, see the DXR Stock Forecast page.

Daxor Releases Updated Investor Presentation to Public Markets

Daxor Corporation disclosed that it has made its current investor presentation publicly available, without providing additional operational, financial, or strategic details in the accompanying text. The release signals an effort to update and engage investors, but the lack of substantive content in the filing means the implications for the company’s operations, industry positioning, or stakeholders cannot be determined from this document alone.

The most recent analyst rating on (DXR) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Daxor stock, see the DXR Stock Forecast page.